A cool interstellar comet that for millions of years has drifted in the spaces between our stars is now back in our telescope viewing range and will make its closest approach to Earth this week. We’re ...

Investing.com - TD Cowen initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with a Buy rating on Wednesday, citing the potential of the company’s telitacicept therapy. The stock, currently trading ...

If you have been progressing through Octopath Traveler 0, then you know that one of the primary objectives of the game is to rebuild Wishvale. After all, this town has been your home for years, and it ...

Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...

Vor Biopharma's estimated fair value is US$15.10 based on 2 Stage Free Cash Flow to Equity Vor Biopharma is estimated to be 49% undervalued based on current share price of US$7.68 Our fair value ...

I love being a licensed private pilot. As you may have seen from other videos, I am starting my instrument rating training. I really believe that I will be a much safer pilot when I get my IFR or ...

Vor Bio grants CEO Jean-Paul Kress an option to purchase 83.3 million shares at $0.89, vesting over four years. Vor Bio, a biotechnology company specializing in autoimmune disease treatments, ...

The Plainview-Hale County Airport has submitted a notice of nonconcurrence with the Federal Aviation Administration (FAA) regarding its plan to terminate an instrument flight procedure (IFP) at the ...

For all the cutting edge features found in modern EFB apps, nothing is more important than charts. Having access to always-updated, geo-referenced versions of sectionals, airport diagrams, and ...

Thick fog moves into Mission Valley. (File photo by Chris Stone/Times of San Diego) When a business jet crashed into a Murphy Canyon neighborhood Thursday, its pilots had to cope with one of the ...

Shares of Vor Biopharma (NASDAQ:VOR) continued to tumble on Friday as Baird and Stifel downgraded the gene therapy developer in reaction to its plans to explore strategic alternatives, which led to ...